BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 27, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2027

Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
DEVICE

BioPearl™

TACE

Trial Locations (10)

Unknown

RECRUITING

CUB Hôpital Erasme, Brussels

RECRUITING

UZ Leuven, Leuven

RECRUITING

Beaujon Hospital, Clichy

NOT_YET_RECRUITING

CHU Grenobles (Hôpital Michallon), La Tronche

RECRUITING

Paul-Brousse Hospital, Villejuif

RECRUITING

SLK-Kliniken Heilbronn, Heilbronn

RECRUITING

University Hospital Tübingen, Tübingen

RECRUITING

Fondazione IRCCS Instituto Tumori, Milan

RECRUITING

Fondazione Policlinico Universitario A. Gemelli, Rome

RECRUITING

Città della Salute e della Scienza di Torino, Turin

All Listed Sponsors
lead

Terumo Europe N.V.

INDUSTRY